LY-CoV555, which is being developed in partnership with Canadian biotech AbCellera, is already being studied as a treatment in patients who have contracted the disease. The nursing home trial will test whether it works prophylactically.
The elderly are at particularly high risk for the disease that has claimed more than 690,000 lives globally. To speed the study, the company has created mobile research units including retrofitted recreational vehicles that can be deployed in response to coronavirus outbreaks at nursing homes across the United States.LY-CoV555 belongs to a class of drugs known as monoclonal antibodies, which are among the most widely used biotechnology medicines. Regeneron Pharmaceuticals Inc and other drugmakers are testing similar treatments against COVID-19.
Property Property Latest News, Property Property Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »